The U.S. Food and Drug Administration has granted approval to Merck & Co. (NYSE:MRK) for the use of KEYTRUDA and KEYTRUDA QLEX, in combination with paclitaxel, with or without bevacizumab, to treat ...

Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...

A subcutaneously injected version of Merck cancer immunotherapy Keytruda is now FDA approved, a regulatory decision that gives patients a less burdensome dosing option and provides the pharmaceutical ...

Merck MRK is focusing on driving its long-term growth with its new products and a promising set of pipeline candidates as its blockbuster PD-L1 inhibitor, Keytruda, faces patent expiration in 2028.

Feb 4 (Reuters) - Some cancer therapies may be more effective when given earlier in the day, aligning treatment with the body ...